Open AccessGrowth and bone health in paediatric patients with Crohn's disease receiving subcutaneous tumor necrosis factor antibody
Author(s) -
Judith Pichler
Publication year - 2015
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v21.i21.6613
Subject(s) - medicine , body mass index , gastroenterology , bone mineral , anthropometry , infliximab , adalimumab , crohn's disease , tumor necrosis factor alpha , disease , osteoporosis
To study whether adalimumab (ADA) was associated with improvement in growth, bone mineral density (BMD) and bone metabolism.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom